SCHEMBL5886948

SCHEMBL5886948

Cc1nc(N2CCN(C(=O)NC3CCCCC3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
CNR1 P21554 2/20 0.40
CNR2 P34972 2/20 0.40
P2RX7 Q99572 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GFER P55789 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
SMO Q99835 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886875 0.92 SMN1; SMN2 (0.41) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5886908 0.92 BRAF (0.39) MEN1KMT2ASMN1; SMN2MAPTGFER
SCHEMBL5887195 0.91 EPHX2 (0.44) KMT2ASMN1; SMN2MAPTCNR1CNR2
SCHEMBL5887138 0.88 SMN1; SMN2 (0.44) KMT2ASMN1; SMN2MAPTCNR1CNR2
SCHEMBL5887513 0.88 GFER (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL5886882 0.88 MAPT (0.43) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5887394 0.87 ACHE (0.44) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5886779 0.87 MAPT (0.44) POLBSMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL5887675 0.86 SLC6A7 (0.44) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5887324 0.86 ALDH1A1 (0.37) POLBMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP POLB 77/4885MEN1 2183/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.